^
    1d
    A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer (clinicaltrials.gov)
    P1, N=56, Recruiting, Memorial Sloan Kettering Cancer Center | Active, not recruiting --> Recruiting
    Enrollment open • Checkpoint inhibition • First-in-human
    |
    BRAF (B-raf proto-oncogene)
    |
    PD-L1 expression • BRAF mutation
    |
    Keytruda (pembrolizumab) • MQ710
    1d
    Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304) (clinicaltrials.gov)
    P3, N=89, Completed, Incyte Corporation | Active, not recruiting --> Completed
    Trial completion
    |
    Keytruda (pembrolizumab) • Erbitux (cetuximab) • cisplatin • carboplatin • 5-fluorouracil • epacadostat (INCB024360)
    1d
    AI-driven multi-omics integration of cancer-associated fibroblasts for prognostic modeling and therapeutic target discovery in head and neck squamous cell carcinoma. (PubMed, NPJ Precis Oncol)
    Furthermore, therapeutic vulnerabilities were explored by integrating drug sensitivity prediction, AI-assisted cMAP screening, and molecular docking validation, which identified Epothilone B as a promising agent targeting HBEGF. Overall, this research shows that understanding the heterogeneity of CAFs with AI-enabled multi-omics modeling can reveal prognostic biomarkers and therapeutic targets for overcoming resistance, with the ultimate goal of improving precision oncology for HNSCC.
    Journal • Tumor mutational burden
    |
    TMB (Tumor Mutational Burden) • MSI (Microsatellite instability)
    |
    patupilone (EPO 906)
    1d
    Molecular docking and dynamics reveal CCNB2 as a functional target of lncRNA ADAMTS9-AS1-002 in HNSCC. (PubMed, Biochem Biophys Res Commun)
    These findings indicate a strong interaction between lncRNA ADAMTS9-AS1-002 and CCNB2 expression or function, with a substantial contribution to uncontrolled cell proliferation and oncogenic progression in HPV-positive HNSCC. Furthermore, this study also identifies CCNB2 as a critical downstream effector of ADAMTS9-AS1-002, which can be harnessed as a promising molecular signature for therapeutic intervention in head and neck cancers positive for HPV.
    Journal
    |
    CCNB2 (Cyclin B2)
    1d
    Deciphering the oncogenic role of key genes in HNSC: insights from multi-omics and functional studies. (PubMed, Discov Oncol)
    In conclusion, MAPK3, MLLT4, PLAU, and SERPINE1 emerge as promising biomarkers and therapeutic targets for HNSC.
    Journal
    |
    SERPINE1 (Serpin Family E Member 1) • AFDN (Afadin, Adherens Junction Formation Factor) • MAPK3 (Mitogen-Activated Protein Kinase 3) • PLAU (Plasminogen Activator)
    2d
    MULTINECK: Multimodal Prediction of Response to Chemoradiotherapy for Squamous Cell Carcinoma of the Head and Neck (clinicaltrials.gov)
    P=N/A, N=152, Not yet recruiting, Centre Henri Becquerel
    New trial
    2d
    Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC (clinicaltrials.gov)
    P1, N=36, Recruiting, University of Chicago | Active, not recruiting --> Recruiting
    Enrollment open
    |
    Keytruda (pembrolizumab) • Erbitux (cetuximab) • zanzalintinib (XL092)
    2d
    Pembrolizumab and Lenvatinib After Definitive Chemoradiation of Locally Advanced HNSCC (clinicaltrials.gov)
    P2, N=50, Active, not recruiting, Universität des Saarlandes | Recruiting --> Active, not recruiting | Trial completion date: Sep 2026 --> Jan 2027 | Trial primary completion date: Sep 2025 --> Jan 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • Lenvima (lenvatinib)
    2d
    CAV2-expressing nerves induce metabolic switch toward mitochondrial oxidative phosphorylation to promote cancer stemness. (PubMed, Nat Commun)
    This interplay observed between cancer cells, neurons, and glial cells suggests a potential mechanism through which tumor-associated nerves might influence cancer stemness via metabolic reprogramming. This highlights a possible direction for anticancer therapy that warrants further investigation.
    Journal
    |
    CAV2 (Caveolin 2)
    3d
    RePaIr-HN: Re-Radiochemotherapy and Pembrolizumab vs. Immuno(Chemo)Therapy for Locoregionally Recurrent PD-L1 Positive (CPS≥1) HNSCC (clinicaltrials.gov)
    P3, N=214, Recruiting, Universität des Saarlandes | Not yet recruiting --> Recruiting | Initiation date: Jul 2025 --> Oct 2025
    Enrollment open • Trial initiation date
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • 5-fluorouracil
    3d
    A Study of Tooth Erosion in People With Esophagogastric Cancer (clinicaltrials.gov)
    P=N/A, N=300, Recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Nov 2025 --> Nov 2026 | Trial primary completion date: Nov 2025 --> Nov 2026
    Trial completion date • Trial primary completion date
    3d
    Multi-omics revealed GOT1/ALDH3A1 pathway attenuated head and neck squamous cell carcinoma and increased cisplatin sensitivity through ROS induced by mitochondrial dysfunction. (PubMed, Redox Rep)
    RNA-seq further identified aldehyde dehydrogenase 3A1 (ALDH3A1) as potentially downstream target of GOT1. These findings suggest that GOT1 knockdown may improve clinical outcomes in HNSCC.
    Journal
    |
    ALDH3A1 (Aldehyde Dehydrogenase 3 Family Member A1)
    |
    cisplatin